Amneal Pharmaceuticals Inc
For the period ended Dec 31, 2024. Filed Feb 28, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 28, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| Date: February 28, 2025 | Amneal Pharmaceuticals, Inc. | |
|---|---|---|
| By: | /s/ Anastasios Konidaris | |
| Anastasios Konidaris | ||
| Executive Vice President, Chief Financial Officer(Principal Financial and Accounting Officer) | ||
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| Signature | Title | Date |
|---|---|---|
| /s/ Chirag Patel | President, Co-Chief Executive Officer and Director | February 28, 2025 |
| Chirag Patel | (Co-Principal Executive Officer) | |
| /s/ Chintu Patel | Co-Chief Executive Officer and Director | February 28, 2025 |
| Chintu Patel | (Co-Principal Executive Officer) | |
| /s/ Anastasios Konidaris | Executive Vice President, Chief Financial Officer | February 28, 2025 |
| Anastasios Konidaris | (Principal Financial and Accounting Officer) | |
| /s/ Paul M. Meister | February 28, 2025 | |
| Paul M. Meister | Chairman of the Board and Director | |
| /s/ Emily Peterson Alva | February 28, 2025 | |
| Emily Peterson Alva | Director | |
| /s/ Deb Autor | February 28, 2025 | |
| Deb Autor | Director | |
| /s/ J. Kevin Buchi | February 28, 2025 | |
| J. Kevin Buchi | Director | |
| /s/ Jeffrey P. George | February 28, 2025 | |
| Jeffrey P. George | Director | |
| /s/ John J. Kiely, Jr. | February 28, 2025 | |
| John J. Kiely, Jr. | Director | |
| /s/ Ted Nark | February 28, 2025 | |
| Ted Nark | Director | |
| /s/ Gautam Patel | February 28, 2025 | |
| Gautam Patel | Director | |
| /s/ Shlomo Yanai | February 28, 2025 | |
| Shlomo Yanai | Director |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.